Jul 12, 2024, 08:30
News
IR
Swedish
Regulatory
MAR
Report
Interim
Q2
Jul 12, 2024, 08:30
News
IR
English
Regulatory
MAR
Report
Interim
Q2
May 24, 2024, 17:35
News
IR
English
Report
Annual
May 21, 2024, 11:15
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
May 15, 2024, 13:50
News
IR
English
Regulatory
MAR
Corporate Action
Other
May 15, 2024, 13:50
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
May 06, 2024, 08:30
News
IR
Swedish
Corporate Action
Other
May 06, 2024, 08:30
News
IR
English
Corporate Action
Other
Apr 25, 2024, 08:30
News
IR
Swedish
Regulatory
Listing Regulation
Report
Annual
Apr 19, 2024, 09:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Mar 11, 2024, 09:57
News
IR
Swedish
Corporate Action
Other
Mar 11, 2024, 09:57
News
IR
English
Corporate Action
Other
Mar 06, 2024, 13:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Mar 05, 2024, 10:45
News
IR
English
Corporate Action
Other
Mar 05, 2024, 10:45
News
IR
Swedish
Corporate Action
Other
Feb 15, 2024, 20:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Feb 15, 2024, 19:35
News
IR
English
Regulatory
MAR
Report
Interim
Yearend
Feb 15, 2024, 19:35
News
IR
Swedish
Regulatory
MAR
Report
Interim
Yearend
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 70 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
VP Business Development
Roger Lassing
Mail: roger.lassing@iconovo.se
CEO
Johan Wäborg
Mail: johan.waborg@iconovo.se